Loading...
Loading...
ACADIA Pharmaceuticals
ACAD
announced Thursday the publication of data from its pivotal Phase III -020 Study
with pimavanserin in patients with Parkinson's disease psychosis (PDP)
in the November 1, 2013 online issue of The Lancet. In the -020
Study, pimavanserin demonstrated significant and clinically meaningful
benefits and was safe and well tolerated in patients with PDP.
Pimavanserin significantly reduced psychosis and maintained motor
control in patients with PDP. Significant benefits were also observed in
exploratory measures of nighttime sleep, daytime wakefulness and
caregiver burden.
“Among Parkinson's patients,
See full press release© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
We simplify the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in